Navigation Links
Gene Can Dampen Chemo Drug Effectiveness
Date:6/10/2009

Alternatives to current breast cancer therapy needed for some patients, study says

WEDNESDAY, June 10 (HealthDay News) -- Women with a certain type of gene may show marked resistance to an important chemotherapy drug used to treat breast cancer, new research suggests.

Scientists at the U.S. National Cancer Institute (NCI) suspect that the variation in the SOD2 gene affects how a patient responds to cyclophosphamide, an agent used against breast tumors, blood cancers and other malignancies. The research is the first to show a mechanism and a biomarker for cyclophosphamide resistance.

Although this is not good news for some patients, the findings have a silver lining: New tests may soon be developed to help doctors screen for genetic markers and create "tailored" therapies, according to an NCI news release.

"In the future, such tests may be used to guide the treatment of patients with the SOD2 variation, ensuring that they receive a therapy that is more effective than cyclophosphamide-based therapy," senior study author Stefan Ambs, of the NCI's Center for Cancer Research, said in the news release.

The study, published online June 9 in Clinical Cancer Research, looked at 588 breast cancer patients in Norway and the United States. Those who had the variation experienced poorer survival on the drug, the researchers found. Scientists believe that the SOD2 variant interferes with the structure and function of an important cellular protein.

More information

The American Cancer Society offers more information on breast cancer.



-- Peter West



SOURCE: U.S. National Cancer Institute, news release, June 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Fallout From Failed AIDS Vaccine Could Dampen Research
2. Drinking Dampens Ability to Feel Fear
3. Autoimmune Disease Treatment May Not Dampen Immune System
4. Economy Doesnt Dampen Colorados Giving Spirit According to Statewide Giving and Volunteering Study
5. Experimental Drug May Dampen Severe Asthma
6. Obesity May Dampen Response to Asthma Meds
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. To evade chemotherapy, some cancer cells mimic stem cells
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Can Dampen Chemo Drug Effectiveness 
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized autonomous ... Ethereum blockchain, has released their technical specifications . , 2017 has seen an ... systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder ...
(Date:6/27/2017)... Orlando, FL (PRWEB) , ... June 27, 2017 ... ... the leading payment solution for many of the health care industry’s hospitals and ... its new patient financing portal for select customers. Parasail Health is a San ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... AVIV, Israel , June 27, 2017  Therapix ... specialty clinical-stage pharmaceutical company specializing in the development of ... The Nasdaq Stock Market Opening Bell in ... 2017 in honor of its initial public offering (IPO) ... Capital Market in March 2017. Dr. Elran ...
(Date:6/27/2017)... 27, 2017   NuEyes (NuEyes Technologies Inc.) today ... fuel its growth in helping the legally blind live more ... Group), the leading developer of augmented, virtual and mixed reality ... The undisclosed funding amount was provided by strategic partners ... with offices in Abu Dhabi , ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 ... that validate the use of MMprofiler with SKY92, the ... myeloma (MM). In a poster presentation at the 22 ... in Madrid, Spain , SkylineDx researchers ... high-risk elderly patients. In a separate ...
Breaking Medicine Technology: